Morgan A J, Allison A C, Finerty S, Scullion F T, Byars N E, Epstein M A
Department of Pathology, University of Bristol Medical School, University Walk, England.
J Med Virol. 1989 Sep;29(1):74-8. doi: 10.1002/jmv.1890290114.
The efficacy of a new vaccine preparation against Epstein-Barr (EB) virus was investigated in cotton-top tamarins. The vaccine consists of fast protein liquid chromatography-purified EB virus membrane antigen glycoprotein of 340 Kd (MA gp340) mixed with a synthetic muramyl dipeptide adjuvant emulsified in squalane containing a pluronic polymer; it is suitable for both scaled-up batch production and eventual administration to man. Vaccinated tamarins rapidly developed ELISA detectable high titre antibodies to MA gp340, and their sera became strongly EB virus-neutralising. After challenge with a massive 100% carcinogenic dose of EB virus, the vaccinated tamarins had a strikingly low level of circulating EB virus-carrying mononuclear cells, in contrast to a control animal, and remained entirely free of tumours. This first-generation vaccine has thus been validated in experimental animals and the way opened for a phase I human trial.
在棉顶狨猴中研究了一种针对爱泼斯坦 - 巴尔（EB）病毒的新型疫苗制剂的疗效。该疫苗由快速蛋白质液相色谱纯化的340Kd EB病毒膜抗原糖蛋白（MA gp340）与合成的胞壁酰二肽佐剂混合而成，该佐剂乳化在含有普朗尼克聚合物的角鲨烷中；它既适合大规模批量生产，最终也适合给人类使用。接种疫苗的狨猴迅速产生了ELISA可检测到的针对MA gp340的高滴度抗体，并且它们的血清具有很强的EB病毒中和能力。在用100%致癌剂量的EB病毒进行攻击后，与对照动物相比，接种疫苗的狨猴循环携带EB病毒的单核细胞水平极低，并且完全没有肿瘤。因此，这种第一代疫苗已在实验动物中得到验证，并为I期人体试验开辟了道路。
